News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
V: We will succeed!! Don't be doubtful! Once it will starts Trading it will rocket up fast!!
Hoeever, it could happened sooner!!
The latest update is that we are waiting for the completion of the Audit which could be completed in 1-3 wks! Once the Audit is completed, then it will be followed by the filing of form 10 to be submitted to the OTC and SEC!! Once it is approved by SEC ! I think we will be pink current! Then we are ready for Trading! Probably another additional 3wks!! You have to be patient in this world to succeed!!
Pls read the postings below for the last 5 days!
This will go to Nasdaq from OTC!!
Luckyyu: when this go to a dollar, it will rocket up quickly!! Especially when there is a merger coming up, hopefully, Sensoria!!
Welcome to Lifeline Biotechnologies Inc. (LLBO) Board!!!
Clinical Trial
In Progress - To Be Completed
** Funding for Clinical Trial
** Vendor delivery of testing materials
Completed for Clinical Trial
** Protocol for testing accepted
** Internal Review Board (IRB) approved
** Contract with hospital executed
Prospective Partner
** Stanford University's Canary Research
Research in blood genomics
The Mastascope is an ultraslim, hand held endoscope designed to enter the breast nipple via one of its milk ducts, thus permitting the physician to visualize the interior aspects of the breast. Because many cancers actually begin within an individual milk duct, these intraductal tumors are visualized easily and can be biopsied. This product has been used in leading breast centers in the United Kingdom and other countries with great success. Lifeline has obtained a CE mark for marketing and distribution in Europe.
Lifeline has developed and tested an ultraslim endoscope to directly visualize the ovarian surface in the search for cancer. This is of great advantage to physicians, because neither MRI, X-Ray nor Ultrasonography can provide accurate assessments of subtle surface changes. Initial reports of clinical usage have been encouraging.
About $LLBO - Lifeline Biotechnologies, Inc.
About Lifeline Biotechnologies:
Lifeline Biotechnologies, Inc. (OTC Market: LLBO) founded in 1994 is based in Reno, NV. LLBO has invested over $10M in a device and process for early detection of breast tissue abnormalities some of which are cancerous or pre-cancer. Three “Proof of Concept” clinical trials of over 500 women have been completed and three patents (one hardware, two software) have been awarded.
Safe Harbor:
This publication includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, the ability to obtain financing, successful development of the Company's product or market acceptance of the product and regulatory and shareholder approval for anticipated actions.
http://www.firstwarningsystems.com/ became Cyrcadia Health http://cyrcadiahealth.com/
http://www.lbti.com
$LLBO is Cyrcadia's largest shareholder at approximately 40%.
Transfer Agent
OTC Corporate Transfer Service Co.
52 Maple Run Drive
Jericho, NY 11753
| Shares Outstanding | 3,026,680,967 | a/o Sep 30, 2014 |
| Float | 650,000,000 | a/o Jun 30, 2009 |
| Authorized Shares | 4,950,000,000 | a/o Sep 30, 2014 |
| Par Value | 0.001 |
About Lifeline Biotechnologies:
Lifeline Biotechnologies, Inc. (OTC Market: LLBO) founded in 1994 is based in Reno, NV. LLBO has invested over $10M in a device and process for early detection of breast tissue abnormalities some of which are cancerous or pre-cancer. Three “Proof of Concept” clinical trials of over 500 women have been completed and three patents (one hardware, two software) have been awarded. http://www.lbti.com
Cyrcadia Health founded in 2008, is based in Reno, Nev. The Cyrcadia Health product line is a device and software service that detects breast tissue abnormalities leading to health risk assessment and management including early breast cancer identification. Three clinical trials with over 650 participants have achieved proof of concept and superior outcomes when compared to other diagnostic protocols. Cyrcadia Health technology is exclusively licensed for development, manufacturing and marketing worldwide from Lifeline Biotechnologies, Inc (OTC Market: LLBO). Cyrcadia Health is planning a final, limited clinical trial and a 510k device classification to validate the fourth generation of the FWS product. Cyrcadia Health is preparing to apply for a Euro CE Mark to market in the European Union and Asia Pacific markets. See Cyrcadia Health video, “Breast Cancer Tumor Progression” at http://www.cyrcadiahealth.com/
iTBra in the News
ABC 7 News - February 5, 2015
They also interviewed Rob Royea (Cyrcadia's President) for a feature story on Good Morning America expected to air in the next coming months.
https://mobile.twitter.com/RobRoyea/status/564872820635627520
Could a Bra Actually Detect Breast Cancer?
By Smithsonian Magzine
http://www.smithsonianmag.com/innovation/could-a-bra-actually-detect-breast-cancer-180954612/?utm_source=twitter.com&no-ist
...Cyrcadia prepares to enter the final clinical trials that will be conducted at El Camino Hospital (ECH) in Mountain View, CA and the Ohio State University (OSU) Oncology Hospital in Columbus, OH. The trials have been approved through Investigational Review Boards (IRB's) of ECH and are currently undergoing the review process at OSU. The ECH trial is slated for start before the end of April 2015. The trials are expected to be completed in four to 6 months. On completion Cyrcadia will obtain CE Marking allowing for sales and marketing outside of the USA. On completion of the trials Cyrcadia will be submitting a 510(k) to the FDA. Post clearance, marketing will begin in the USA. International sales are expected in Q4 of 2015 and US sales in Q1 or Q2 of 2016.
It is interesting to note that Dr. Farrar at OSU will be the primary investigator for the trials conducted at OSU. Dr. Farrar headed the original "proof of concept" study that was conducted at OSU.
Stanford University Canary Center for Early Cancer Detection has pledged $187,000 to help fund the equipment for the trials at El Camino Hospital.
They also interviewed Rob Royea (Cyrcadia's President) for a feature story on Good Morning America expected to air in the next coming months.
AI
